Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 7/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 9/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24676843 | 0.83 | S1PR5 (0.38) | SLC6A1 | |
| SCHEMBL1464302 | 0.82 | SLC6A11 (0.49) | SLC6A1SLC6A11SLC6A12MEN1TP53 | |
| SCHEMBL25351419 | 0.80 | LMNA (0.45) | — | |
| SCHEMBL23557995 | 0.79 | SLC6A11 (0.47) | SLC6A1SLC6A11SLC6A12MEN1TP53 | |
| SCHEMBL13605164 | 0.79 | SLC6A11 (0.47) | SLC6A1SLC6A11SLC6A12MEN1TP53 | |
| SCHEMBL22978741 | 0.78 | SLC6A1 (0.46) | SLC6A1CYP1A2 | |
| SCHEMBL16012677 | 0.77 | SLC6A1 (0.49) | SLC6A1SLC6A11SLC6A12MEN1TP53 | |
| SCHEMBL6991991 | 0.77 | SLC6A1 (0.49) | SLC6A1SLC6A11SLC6A12MEN1TP53 | |
| SCHEMBL740141 | 0.76 | SMN1; SMN2 (0.54) | SLC6A1CYP1A2 | |
| SCHEMBL771607 | 0.76 | SMN1; SMN2 (0.54) | SLC6A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | SLC6A1 1645/4885SLC6A11 1363/4885SLC6A12 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.